Study of Secukinumab With 2 mL Pre-filled Syringes
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 214
- Registration Number
- NCT02748863
- Locations
- 🇬🇧
Novartis Investigative Site, Surrey, United Kingdom
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
- Conditions
- Psoriatic Arthritis
- Interventions
- Biological: SecukinumabBiological: Adalimumab
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 853
- Registration Number
- NCT02745080
- Locations
- 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom
Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 92
- Registration Number
- NCT02740270
- Locations
- 🇪🇸
Novartis Investigative Site, Barcelona, Catalunya, Spain
Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
- Conditions
- Advanced or Metastatic ER+ Breast Cancer
- Interventions
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 199
- Registration Number
- NCT02734615
- Locations
- 🇺🇸
MD Anderson Cancer Center SC - LSZ102X2101, Houston, Texas, United States
🇺🇸Massachusetts General Hospital Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2016-04-08
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 104
- Registration Number
- NCT02732119
- Locations
- 🇺🇸
Florida Cancer Specialists FL Cancer Specialists, Fort Myers, Florida, United States
🇺🇸St. Luke's Cancer Institute Regulatory, Kansas City, Missouri, United States
🇺🇸Research Medical Center HCA Midwest Division, Kansas City, Missouri, United States
Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement
- Conditions
- Axial Psoratic Arthritis
- Interventions
- Biological: Secukinumab
- First Posted Date
- 2016-03-29
- Last Posted Date
- 2020-10-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 503
- Registration Number
- NCT02721966
- Locations
- 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom
A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-03-28
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT02720510
- Locations
- 🇺🇸
David Geffen School of Medicine at UCLA UCLA, Los Angeles, California, United States
🇺🇸Northside Hospital Central Research Dept., Atlanta, Georgia, United States
🇺🇸Oncology Hematology West Nebraska Cancer Specialists dbaNebraska Cancer Specialists, Omaha, Nebraska, United States
Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation
- First Posted Date
- 2016-03-28
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 53
- Registration Number
- NCT02720536
- Locations
- 🇮🇹
Novartis Investigative Site, Napoli, Italy
Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2019-02-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 133
- Registration Number
- NCT02720107
- Locations
- 🇩🇪
Novartis Investigative Site, Unterhaching, Germany
Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD)
- Conditions
- Inherited Metabolic Disorders IMD
- Interventions
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2018-11-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02715505